Based in Woodbridge, CT, GlyGenix Therapeutics, Inc. is a privately held biotech company developing therapeutic solutions for severe metabolic disorders. The company's initial focus is in using gene therapy products with non-viral delivery systems for the treatment of Glycogen Storage Disease Type 1a (GSD1a), a rare and severe chronic genetic liver disease for which no approved therapies exist. Founded in 2006, and with the aid of a sizable body of pre-clinical data, GlyGenix Therapeutics, Inc is poised to expedite the initiation of clinical trials for the treatment of GSD1a.
View Top Employees from GlyGenix, Inc.| Website | http://glygenix.com |
| Revenue | $8.2 million |
| Funding | $150000 |
| Employees | 1 (0 on RocketReach) |
| Address | 15 Research Drive, Woodbridge, Connecticut 06525, US |
| Phone | (203) 397-3637 |
| Industry | Business Services General, Business Services |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular GlyGenix, Inc. employee's phone or email?
GlyGenix, Inc. Questions
The GlyGenix, Inc. annual revenue was $8.2 million in 2023.
GlyGenix, Inc. is based in Woodbridge, Connecticut.
The NAICS codes for GlyGenix, Inc. are [3254, 325, 32].
The SIC codes for GlyGenix, Inc. are [28, 283].
Related Companies
